Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00262964 · ClinicalTrials.gov registry record · NA

Obesity and Nonalcoholic Fatty Liver Disease

A NA study, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
51
Enrollment target

NCT00262964 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 51 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00262964, a NA study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target

Study Summary

The primary goal of this study is to provide a better understanding of: 1) the pathogenesis and pathophysiology of non-alcoholic fatty liver disease (NAFLD) in obese subjects, and 2) the effect of marked weight loss on the histologic and metabolic abnormalities associated with NAFLD. The following hypotheses will be tested: 1. obesity causes hepatic fat accumulation because of excessive fatty acid release from fat tissue and increased free fatty acid availability, 2. increased hepatic (liver) fat content causes insulin-resistant glucose (sugar) production by the liver and altered liver protein synthesis, 3. increased hepatic fat content causes increased lipid (fat) peroxidation, hepatic inflammation, necrosis and fibrosis, and 4. marked weight loss improves NAFLD once patients are weight stable.

Interventions

  • DRUG Niacin
  • DRUG placebo
  • DRUG fenofibrate

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2004-10
Est. Completion 2008-12
Phase NA

What the Registry Record Tells You About NCT00262964

The ClinicalTrials.gov registry entry for NCT00262964 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Niacin is the first listed.

NCT00262964 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00262964 about?

NCT00262964 is a clinical study titled "Obesity and Nonalcoholic Fatty Liver Disease". The primary goal of this study is to provide a better understanding of: 1) the pathogenesis and pathophysiology of non-alcoholic fatty liver disease (NAFLD) in obese subjects, and 2) the effect of marked weight loss on the histologic and metabolic abnormalities associated with NAFLD. The following h...

What is the current status of trial NCT00262964?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2004-10. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00262964?

The interventions under investigation include: Niacin (DRUG), placebo (DRUG), fenofibrate (DRUG).

Who is sponsoring clinical trial NCT00262964?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.